[1] LIAN Z， XIE Y， LU Y,et al Trends in the major causes of death in China， 1982-2010 [J] Chin Med J（中华医学杂志英文版）， 2014，127(4)：777-781
[2] LIU L Cardiovascular diseases in China [J] Biochem Cell Biol,2007，85(2)：157-163
[3] MORAN A， GU D， ZHAO D,et al Future cardiovascular disease in china： markov model and risk factor scenario projections from the coronary heart disease policy model-china [J] Circ Cardiovasc Qual Outcomes,2010，3(3)：243-252
[4] STONE N J， ROBINSON J G， LICHTENSTEIN A H,et al 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults： a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [J] J Am Coll Cardiol,2014，63(25 Pt B)：2889-2934
[5] AVIS H J， HUTTEN B A， GAGNE C,et al Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia [J] J Am Coll Cardiol,2010，55(11)：1121-1126
[6] MORIARTY P M， JACOBSON T A， BRUCKERT E,et al Efficacy and safety of alirocumab， a monoclonal antibody to PCSK9， in statin-intolerant patients： design and rationale of ODYSSEY ALTERNATIVE， a randomized phase 3 trial [J] J Clin Lipidol,2014，8(6)：554-561
[7] REINER Z， CATAPANO A L， DE BACKER G,et al ESC/EAS Guidelines for the management of dyslipidaemias： the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) [J] Eur Heart J,2011，32(14)：1769-1818
[8] ABIFADEL M， VARRET M， RABES J P,et al Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J] Nat Genet,2003，34(2)：154-156
[9] DIAS C S， SHAYWITZ A J， WASSERMAN S M,et al Effects of AMG 145 on low-density lipoprotein cholesterol levels： results from 2 randomized， double-blind， placebo-controlled， ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins [J] J Am Coll Cardiol,2012，60(19)：1888-1898
[10] STEIN E A， MELLIS S， YANCOPOULOS G D,et al Effect of a monoclonal antibody to PCSK9 on LDL cholesterol [J] N Engl J Med,2012，366(12)：1108-1118
[11] LUNVEN C， PAEHLER T， POITIERS F,et al A randomized study of the relative pharmacokinetics， pharmacodynamics， and safety of alirocumab， a fully human monoclonal antibody to PCSK9， after single subcutaneous administration at three different injection sites in healthy subjects[J] Cardiovasc Ther,2014，32(6)：297-301
[12] KOREN M J， SCOTT R， KIM J B,et al Efficacy， safety， and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL)： a randomised， double-blind， placebo-controlled， phase 2 study [J] Lancet,2012，380(9858)：1995-2006
[13] GIUGLIANO R P， DESAI N R， KOHLI P,et al Efficacy， safety， and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57)： a randomised， placebo-controlled， dose-ranging， phase 2 study [J] Lancet,2012，380(9858)：2007-2017
[14] HIRAYAMA A， HONARPOUR N， YOSHIDA M,et al Effects of evolocumab (AMG 145)， a monoclonal antibody to PCSK9， in hypercholesterolemic， statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study [J] Circ J,2014，78(5)：1073-1082
[15] RAAL F， SCOTT R， SOMARATNE R,et al Low-density lipoprotein cholesterol-lowering effects of AMG 145， a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia： the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial [J] Circulation,2012，126(20)：2408-2417
[16] SULLIVAN D， OLSSON A G， SCOTT R,et al Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients： the GAUSS randomized trial [J] JAMA,2012，308(23)：2497-2506
[17] KOREN M J， GIUGLIANO R P， RAAL F J,et al Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia： 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial [J] Circulation,2014，129(2)：234-243
[18] MCKENNEY J M， KOREN M J， KEREIAKES D J,et al Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease， SAR236553/REGN727， in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy [J] J Am Coll Cardiol,2012，59(25)：2344-2353
[19] ROTH E M， MCKENNEY J M， HANOTIN C,et al Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia [J] N Engl J Med,2012，367(20)：1891-1900
[20] STEIN E A， GIPE D， BERGERON J,et al Effect of a monoclonal antibody to PCSK9， REGN727/SAR236553， to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy： a phase 2 randomised controlled trial [J]. Lancet,2012，380(9836)：29-36
[21] KOREN M J， LUNDQVIST P， BOLOGNESE M,et al Anti-PCSK9 monotherapy for hypercholesterolemia： the MENDEL-2 randomized， controlled phase III clinical trial of evolocumab [J] J Am Coll Cardiol,2014，63(23)：2531-2540
[22] ROBINSON J G， NEDERGAARD B S， ROGERS W J,et al Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia： the LAPLACE-2 randomized clinical trial [J] JAMA,2014，311(18)：1870-1882
[23] RAAL F J， STEIN E A， DUFOUR R,et al PCSK9 Inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2)： a randomised， double-blind， placebo-controlled trial[J] Lancet,2015，385（9965）：331-340.
[24] STROES E， COLQUHOUN D， SULLIVAN D,et al Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance： The GAUSS-2 randomized， placebo-controlled phase 3 clinical trial of evolocumab [J] J Am Coll Cardiol,2014，63(23)：2541-2548
[25] RAAL F J， HONARPOUR N， BLOM D J,et al Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B)： a randomised， double-blind， placebo-controlled trial[J]Lancet,2014，385(14)：341-350.
[26] BLOM D J， HALA T， BOLOGNESE M,et al A 52-week placebo-controlled trial of evolocumab in hyperlipidemia [J] N Engl J Med,2014，370(19)：1809-1819
[27] ROTH E M， DILLER P Alirocumab for hyperlipidemia： physiology of PCSK9 inhibition， pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody [J] Future Cardiol,2014，10(2)：183-199
[28] ROTH E M， TASKINEN M R， GINSBERG H N,et al Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia： results of a 24 week， double-blind， randomized Phase 3 trial [J] Int J Cardiol,2014，176(1)：55-61